Fangzheng Liu

Fangzheng Liu

Auto-generated profile, based on publicly available information

Fangzheng Liu

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
SLSi Li
Si Li
WLWei Li
Wei Li
YMYuqi Miao
Yuqi Miao
MGMeixi Gao
Meixi Gao
JYJia yanfei
Jia yanfei
QWQing-Feng Wu
Qing-Feng Wu
Tumors occurring along the hypothalamus-pituitary axis receive axonal projection from neuroendocrine neurons, but it remains unclear whether neuroendocrine neuronal activity drives tumor expansion. Craniopharyngioma is a common suprasellar tumor with a propensity for invading the hypothalamus, leading to devastating endocrine and metabolic disorders. Here, we developed two autochthonous animal models that faithfully recapitulate the molecular pathology, clinical manifestations, and transcriptomic profiles of papillary craniopharyngioma. Using high-throughput drug screening, we identified 74 compounds with potent antitumor efficacy. The administration of ( S )-amlodipine besylate achieved tumor regression in vivo, potentially by abrogating calcium transients and neuron-to-tumor chemical transmission. Chemogenetic manipulation of neuroendocrine neuronal activity bidirectionally regulated tumor cell growth in our mouse model, suggesting that craniopharyngioma hijacks hypothalamic neurons to promote tumor progression. These findings deepen our understanding of suprasellar tumor biology and offer promising avenues for clinical exploration of effective chemotherapies.

10 December 2024 in The FASEB Journal
Verified
Journal Article
Open access
YXYouchao Xiao
Youchao Xiao
WWWentao Wu
Wentao Wu
FLFangzheng Liu
Fangzheng Liu
LJLu Jin
Lu Jin
JYJia yanfei
Jia yanfei
SGSongbai Gui
Songbai Gui
Obesity presents a significant challenge in managing patients with craniopharyngioma (CP). Cyst fluid (CF), rich in inflammatory mediators, is implicated in CP‐related obesity, though the precise mechanism remains unclear. This study investigated the impact of CF or C‐X‐C motif chemokine ligand‐1 (CXCL1) injections on body weight, Lee index, plasma lipid profiles, hepatic lipid accumulation, leptin levels, NF‐κB pathway, the suppressor of cytokine signaling 3 (SOCS3) expression, and leptin sensitivity in rats. Bioinformatics was employed to identify differentially expressed genes (DEGs) between CF/CXCL1‐treated and control SY5Y cells, as well as to confirm enriched pathways. Western blotting was used for experimental validation, including the effects of sodium salicylate (SS) on leptin sensitivity in SY5Y cells. Injecting CF or CXCL1 into the brain, without hypothalamic damage, led to increased body weight, Lee index, and hepatic lipid accumulation in rats, alongside elevated fasting blood glucose, triglycerides, and total cholesterol, while high‐density lipoprotein cholesterol levels decreased. Additionally, CF and CXCL1 could induce elevated leptin levels, a higher leptin‐to‐body weight ratio, and resistance to exogenous leptin by activating the NF‐κB pathway and upregulating the expression of SOCS3 in rats. Further validation confirmed that CF and CXCL1 suppress leptin signaling by activating the NF‐κB pathway and upregulating SOCS3. Moreover, SS mitigated the inhibitory effects of CF or CXCL1 on leptin signaling, preserving leptin sensitivity in SY5Y cells. These results highlight the obesogenic role of CF and CXCL1, offering insights into the development of morbid obesity through inflammatory factor‐mediated leptin resistance, independent of hypothalamic damage. SS may serve as a promising therapeutic approach for CP‐associated obesity, though additional clinical studies are necessary to confirm its efficacy.